Hospital Infection Therapeutics Market Trends, Size, Growth Factors and Analysis Till 2027

According to IMARC Group’s latest report, titled “Hospital Infection Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027”, the global hospital infection therapeutics market size reached US$ 11.2 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 15.1 Billion by 2027, exhibiting a growth rate (CAGR) of 4.97% during 2022-2027.

Hospital infection therapeutics refers to drugs or medications used to treat diseases or infections. They can be acquired from viral, bacterial and fungal pathogens present in hospitals, nursing homes, rehabilitation centers, outpatient clinics, and other treatment centers. Therapeutics, such as antibacterial, antiviral, antifungal, and infection-based drugs, are used to prevent hospital-acquired infections (HAIs) like urinary tract infections (UTI), pneumonia, surgical site infection, and bloodstream infections (BSI).

Request For a PDF Sample Report: https://www.imarcgroup.com/hospital-infection-therapeutics-market/requestsample

Note: We are in the process of updating our reports. If you want to receive the latest research data covering the period from 2023 to 2028, along with industry trends, market size, and competitive analysis, click on the request sample report. The team would be able to deliver the latest version of the report in a quick turnaround time.

Hospital Infection Therapeutics Market Trends:

The global hospital infection therapeutics market is primarily driven by the rising prevalence of chronic diseases that have increased hospital admissions and cases of HAIs. The growing geriatric population and rising healthcare expenditure are also escalating the demand for these therapeutics. Furthermore, there has been a development of advanced therapies, drugs, vaccines and coverings can be used for the treatment of infections with specific symptoms. Moreover, extensive investment in research and development (R&D) activities to develop new HAI drugs, such as Zerbaxa by Merck & Co., for the treatment of ventilator-associated bacterial pneumonia (VABP), are expected to influence the market growth in the near future.

Competitive Landscape with Key Players:

The report has also analysed the competitive landscape of the market with some of the key players.

• Allergan Plc (AbbVie Inc.)
• AstraZeneca Plc
• Bayer Aktiengesellschaft
• Bristol-Myers Squibb Company
• Hoffmann-La Roche AG (Roche Holding AG)
• Gilead Sciences Inc.
• GlaxoSmithKline plc
• Johnson & Johnson
• Merck & Co. Inc
• Pfizer Inc.
• Sanofi S.A.

Key Market Segmentation:

The report has categorized the market based on drug type and indication.

Breakup by Drug Type:

• Anti-bacterial Drugs
• Anti-fungal Drugs
• Anti-viral Drugs
• Others

Breakup by Indication:

• Blood Stream Infections
• Urinary Tract Infections
• Surgical Site Infections
• Pneumonia
• Others

Breakup by Region:

• North America (United States, Canada)
• Europe (Germany, France, United Kingdom, Italy, Spain, Others)
• Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, South Africa, Others)

Key highlights of the report:

• Market Performance (2016-2021)
• Market Outlook (2022-2027)
• Market Trends
• Market Drivers and Success Factors
• Impact of COVID-19
• Value Chain Analysis
• Comprehensive mapping of the competitive landscape

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group

134 N 4th St.

Brooklyn, NY 11249, USA

Email: Sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

Americas: – +1 631 791 1145 | Africa and Europe: – +44-702-409-7331 | Asia: +91-120-433-0800